Treatment of recalcitrant granuloma annulare (GA) with adalimumab: A single-center, observational study

Journal of the American Academy of Dermatology

Volumn 74, Issue 1, 2016, Pages 127-133

  Min, Michelle S ^a,b,c   Lebwohl, Mark ^a,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c New York New York and Boston Massachusetts ^*  (United States)

Author keywords

adalimumab; etanercept; granuloma annulare; infliximab; Investigator Global Assessment; treatment; tumor necrosis factor inhibitor

Indexed keywords

ADALIMUMAB; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALOPECIA AREATA; ARTICLE; BODY SURFACE; CAUCASIAN; CLINICAL ARTICLE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERANCE; DRUG WITHDRAWAL; ERYTHEMA; FATIGUE; FEMALE; FOLLOW UP; GRANULOMA ANNULARE; HUMAN; HUMAN TISSUE; MEDICAL CARE; MEDICAL HISTORY; MEDICAL RECORD; OBSERVATIONAL STUDY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SAMPLE SIZE; TREATMENT DURATION; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG ADMINISTRATION; EPIDEMIOLOGY; MALE; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADALIMUMAB; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GRANULOMA ANNULARE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; SAMPLING STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84953639164     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2015.09.015     Document Type: Article

References (21)

1. L.A. Thornsberry, and J.C. English III Etiology, diagnosis, and therapeutic management of granuloma annulare: an update Am J Clin Dermatol 14 4 2013 279 290
2. M.S. Hertl, I. Haendle, G. Schuler, and M. Hertl Rapid improvement of recalcitrant disseminated granuloma annulare upon treatment with the tumor necrosis factor-alpha inhibitor, infliximab Br J Dermatol 152 3 2005 552 555
3. G. Murdaca, B.M. Colombo, G. Barabino, M. Caiti, P. Cangati, and F. Puppo Anti-tumor necrosis factor-α treatment with infliximab for disseminated granuloma annulare Am J Clin Dermatol 11 6 2010 437 439
4. J. Shupack, and K. Siu Resolving granuloma annulare with etanercept Arch Dermatol 142 3 2006 394 395
5. A. Kreuter, P. Altmeyer, and T. Gambichler Failure of etanercept therapy in disseminated granuloma annulare Arch Dermatol 142 9 2006 1236 1237 author reply 1237
6. K.A. Knoell Efficacy of adalimumab in the treatment of generalized granuloma annulare in monozygotic twins carrying the 8.1 ancestral haplotype Arch Dermatol 145 2009 610 611
7. D. Rosmarin, A. LaRaia, S. Schlauder, and et al. Successful treatment of disseminated granuloma annulare with adalimumab J Drugs Dermatol 8 2 2009 169 171
8. S. Werchau, A. Enk, and M. Hartmann Generalized interstitial granuloma annulare-response to adalimumab Int J Dermatol 49 4 2010 457 460
9. H. Kozic, and G.F. Webster Treatment of widespread granuloma annulare with adalimumab J Clin Aesthet Dermatol 4 11 2011 42 43
10. R.G. Langley, S.R. Feldman, J. Nyirady, P. van de Kerkhof, and C. Papavassilis The 5-point Investigator's Global Assessment (IGA) scale: a modified tool for evaluating plaque psoriasis severity in clinical trials J Dermatolog Treat 26 2015 23 31
11. A.A. Navarini, Y. Poulin, A. Menter, Y. Gu, and H.D. Teixeria Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis J Drugs Dermatol 13 5 2014 554 562
12. C. Zschoche, M. Bidier, and E. Hadaschik Alopecia areata during treatment with adalimumab: therapy with an alternative TNF-alpha inhibitor is possible J Dtsch Dermatol Ges 11 5 2013 450 453
13. S.A. Beuchner, R.K. Winkelmann, and P.M. Banks Identification of T-cell subpopulations in granuloma annulare Arch Dermatol 119 2 1983 125 128
14. M.H. Lowitt, and J.S. Dover Necrobiosis lipoidica J Am Acad Dermatol 25 5 Pt 1 1991 735 748
15. A. Fayyazi, S. Schweyer, B. Eichmeyer, and et al. Expression of IFNgamma, coexpression of TNFalpha and matrix metalloproteinases and apoptosis of T lymphocytes and macrophages in granuloma annulare Arch Dermatol Res 292 8 2000 384 390
16. M. Mempel, P. Musette, B. Flageul, and et al. T-cell receptor repertoire and cytokine pattern in granuloma annulare: defining a particular type of cutaneous granulomatous inflammation J Invest Dermatol 118 6 2002 957 966
17. R.N. Chavan, J.S. Lehman, and T.J. Flotte Dendritic cells are prominent in granuloma annulare J Am Acad Dermatol 71 5 2014 1020 1022
18. Z. Kaymakcalan, P. Sakora, S. Bose, and et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor Clin Immunol 131 2 2009 308 316
19. K.S. Zhang, L.T. Quan, and S. Hsu Treatment of necrobiosis lipoidica with etanercept and adalimumab Dermatol Online J 15 12 2009 12
20. W.J. Sandborn, S.B. Hanauer, S. Katz, and et al. Etanercept for active Crohn's disease: a randomized, double-blind placebo-controlled trial Gastroenterology 121 5 2001 1088 1094
21. H. Takahasi, K. Kaneta, A. Ishida-Tamamoto, and et al. Sarcoidosis during infliximab therapy for Crohn's disease J Dermatol 37 5 2010 471